These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 15035149)

  • 1. [Carboxyl-terminal propeptide of type I collagen(PICP)].
    Inaba M; Ueda M
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():345-8. PubMed ID: 15035149
    [No Abstract]   [Full Text] [Related]  

  • 2. [Serum PINP(N-terminal propeptide of type I procollagen)].
    Ueda M; Inaba M
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():373-7. PubMed ID: 15035155
    [No Abstract]   [Full Text] [Related]  

  • 3. [N-terminal propeptide of type I procollagen (PINP)].
    Sone T; Fukunaga M
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():232-5. PubMed ID: 15658307
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biochemical markers of bone turnover: Serum P1NP].
    Imanishi Y; Nishizawa Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():231-5. PubMed ID: 18161111
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement of PICP and PINP in the evaluation of pharmaceutical treatment efficacy for osteoporosis].
    Nakatsuka K; Nishizawa Y; Miura M
    Clin Calcium; 2006 Jun; 16(6):977-85. PubMed ID: 16751694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
    Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
    Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Carboxy-terminal propeptide of type I procollagen (PICP)].
    Tanaka Y; Kitajima I
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():244-6. PubMed ID: 15658310
    [No Abstract]   [Full Text] [Related]  

  • 11. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.
    Joerger M; Templeton A; Köberle D; Engler H; Riesen WF; Thürlimann B
    Cancer Chemother Pharmacol; 2011 May; 67(5):1137-44. PubMed ID: 20683595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum.
    Koivula MK; Risteli L; Risteli J
    Clin Biochem; 2012 Aug; 45(12):920-7. PubMed ID: 22480789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y; Tokue A
    Nihon Rinsho; 1998 Aug; 56(8):2072-6. PubMed ID: 9750510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal osteoclastic and osteoblastic responses to exogenous growth hormone in patients with postmenopausal spinal osteoporosis.
    Kassem M; Brixen K; Blum WF; Mosekilde L; Eriksen EF
    J Bone Miner Res; 1994 Sep; 9(9):1365-70. PubMed ID: 7817819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.
    Majkić-Singh N; Ilić M; Ignjatović S; Aleksandra-Postić-Grujin
    Clin Lab; 2002; 48(7-8):407-13. PubMed ID: 12146575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of biochemical bone markers in predicting the response of hormone replacement therapy in perimenopausal cigarette smoking healthy women.
    Cubrilo-Turek M; Stavljenić-Rukavina A; Turek S; Kusec V; Duraković Z
    Coll Antropol; 1999 Jun; 23(1):195-201. PubMed ID: 10402723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP)].
    Fuse H; Nagakawa O; Iwasaki M
    Nihon Rinsho; 2000 Jul; 58 Suppl():163-5. PubMed ID: 11022707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.